FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4365998047> ?p ?o ?g. }

• W4365998047 endingPage "1292" @default.
• W4365998047 startingPage "1277" @default.
• W4365998047 abstract "Anthracycline-taxane chemotherapy for early-stage breast cancer substantially improves survival compared with no chemotherapy. However, concerns about short-term and long-term side-effects of anthracyclines have led to increased use of taxane chemotherapy without anthracycline, which could compromise efficacy. We aimed to better characterise the benefits and risks of including anthracycline, and the comparative benefits of different anthracycline-taxane regimens.We did an individual patient-level meta-analysis of randomised trials comparing taxane regimens with versus without anthracycline, and updated our previous meta-analysis of anthracycline regimens with versus without taxane, as well as analysing 44 trials in six related comparisons. We searched databases, including MEDLINE, Embase, the Cochrane Library, and meeting abstracts to identify trials assessing anthracycline and taxane chemotherapy. Adjuvant or neoadjuvant trials were eligible if they began before Jan 1, 2012. Primary outcomes were breast cancer recurrence and cause-specific mortality. Log-rank analyses yielded first-event rate ratios (RRs) and CIs.28 trials of taxane regimens with or without anthracycline were identified, of which 23 were deemed eligible, and 15 provided data on 18 103 women. Across all 15 trials that provided individual data, recurrence rates were 14% lower on average (RR 0·86, 95% CI 0·79-0·93; p=0·0004) with taxane regimens including anthracycline than those without. Non-breast cancer deaths were not increased but there was one additional acute myeloid leukaemia case per 700 women treated. The clearest reductions in recurrence were found when anthracycline was added concurrently to docetaxel plus cyclophosphamide versus the same dose of docetaxel plus cyclophosphamide (10-year recurrence risk 12·3% vs 21·0%; risk difference 8·7%, 95% CI 4·5-12·9; RR 0·58, 0·47-0·73; p<0·0001). 10-year breast cancer mortality in this group was reduced by 4·2% (0·4-8·1; p=0·0034). No significant reduction in recurrence risk was found for sequential schedules of taxane plus anthracycline when compared with docetaxel plus cyclophosphamide (RR 0·94, 0·83-1·06; p=0·30). For the analysis of anthracycline regimens with versus without taxane, 35 trials (n=52 976) provided individual patient data. Larger recurrence reductions were seen from adding taxane to anthracycline regimens when the cumulative dose of anthracycline was the same in each group (RR 0·87, 0·82-0·93; p<0·0001; n=11 167) than in trials with two-fold higher cumulative doses of non-taxane (mostly anthracycline) in the control group than in the taxane group (RR 0·96, 0·90-1·03; p=0·27; n=14 620). Direct comparisons between anthracycline and taxane regimens showed that a higher cumulative dose and more dose-intense schedules were more efficacious. The proportional reductions in recurrence for taxane plus anthracycline were similar in oestrogen receptor-positive and oestrogen receptor-negative disease, and did not differ by age, nodal status, or tumour size or grade.Anthracycline plus taxane regimens are most efficacious at reducing breast cancer recurrence and death. Regimens with higher cumulative doses of anthracycline plus taxane provide the greatest benefits, challenging the current trend in clinical practice and guidelines towards non-anthracycline chemotherapy, particularly shorter regimens, such as four cycles of docetaxel-cyclophosphamide. By bringing together data from almost all relevant trials, this meta-analysis provides a reliable evidence base to inform individual treatment decisions, clinical guidelines, and the design of future clinical trials.Cancer Research UK, UK Medical Research Council." @default.
• W4365998047 created "2023-04-17" @default.
• W4365998047 creator A5000593393 @default.
• W4365998047 creator A5001256203 @default.
• W4365998047 creator A5001268619 @default.
• W4365998047 creator A5001295833 @default.
• W4365998047 creator A5001406891 @default.
• W4365998047 creator A5001498807 @default.
• W4365998047 creator A5001617286 @default.
• W4365998047 creator A5001753228 @default.
• W4365998047 creator A5002082310 @default.
• W4365998047 creator A5002412211 @default.
• W4365998047 creator A5002979606 @default.
• W4365998047 creator A5004047701 @default.
• W4365998047 creator A5004831613 @default.
• W4365998047 creator A5005643608 @default.
• W4365998047 creator A5005973748 @default.
• W4365998047 creator A5006130493 @default.
• W4365998047 creator A5006337734 @default.
• W4365998047 creator A5006533368 @default.
• W4365998047 creator A5006619488 @default.
• W4365998047 creator A5006665510 @default.
• W4365998047 creator A5007286394 @default.
• W4365998047 creator A5008665323 @default.
• W4365998047 creator A5009137268 @default.
• W4365998047 creator A5010011336 @default.
• W4365998047 creator A5010083380 @default.
• W4365998047 creator A5010293363 @default.
• W4365998047 creator A5010313585 @default.
• W4365998047 creator A5010531543 @default.
• W4365998047 creator A5011410319 @default.
• W4365998047 creator A5011641167 @default.
• W4365998047 creator A5012187098 @default.
• W4365998047 creator A5012681752 @default.
• W4365998047 creator A5012804079 @default.
• W4365998047 creator A5012878855 @default.
• W4365998047 creator A5013493617 @default.
• W4365998047 creator A5013759812 @default.
• W4365998047 creator A5014323257 @default.
• W4365998047 creator A5014363979 @default.
• W4365998047 creator A5014415091 @default.
• W4365998047 creator A5014662741 @default.
• W4365998047 creator A5015740152 @default.
• W4365998047 creator A5016015665 @default.
• W4365998047 creator A5017334876 @default.
• W4365998047 creator A5017411324 @default.
• W4365998047 creator A5019193571 @default.
• W4365998047 creator A5019412832 @default.
• W4365998047 creator A5019992117 @default.
• W4365998047 creator A5020043292 @default.
• W4365998047 creator A5021384685 @default.
• W4365998047 creator A5022237789 @default.
• W4365998047 creator A5023179046 @default.
• W4365998047 creator A5023439496 @default.
• W4365998047 creator A5023558260 @default.
• W4365998047 creator A5024118579 @default.
• W4365998047 creator A5025235757 @default.
• W4365998047 creator A5025364402 @default.
• W4365998047 creator A5025554206 @default.
• W4365998047 creator A5025872642 @default.
• W4365998047 creator A5026659575 @default.
• W4365998047 creator A5026699102 @default.
• W4365998047 creator A5027179093 @default.
• W4365998047 creator A5027201197 @default.
• W4365998047 creator A5027231412 @default.
• W4365998047 creator A5027397937 @default.
• W4365998047 creator A5027517833 @default.
• W4365998047 creator A5027646786 @default.
• W4365998047 creator A5027918729 @default.
• W4365998047 creator A5028664306 @default.
• W4365998047 creator A5028916394 @default.
• W4365998047 creator A5029098621 @default.
• W4365998047 creator A5030234379 @default.
• W4365998047 creator A5030476275 @default.
• W4365998047 creator A5030770401 @default.
• W4365998047 creator A5031675404 @default.
• W4365998047 creator A5032920417 @default.
• W4365998047 creator A5033653230 @default.
• W4365998047 creator A5033695739 @default.
• W4365998047 creator A5034630560 @default.
• W4365998047 creator A5034852608 @default.
• W4365998047 creator A5034902188 @default.
• W4365998047 creator A5035837487 @default.
• W4365998047 creator A5035921302 @default.
• W4365998047 creator A5036252879 @default.
• W4365998047 creator A5036540537 @default.
• W4365998047 creator A5036695602 @default.
• W4365998047 creator A5037659081 @default.
• W4365998047 creator A5038366277 @default.
• W4365998047 creator A5038415411 @default.
• W4365998047 creator A5038448622 @default.
• W4365998047 creator A5038734791 @default.
• W4365998047 creator A5038918684 @default.
• W4365998047 creator A5039121050 @default.
• W4365998047 creator A5039225060 @default.
• W4365998047 creator A5039316545 @default.
• W4365998047 creator A5039704152 @default.
• W4365998047 creator A5039927103 @default.

• next